Literature DB >> 9350619

Chloride conductance in mouse muscle is subject to post-transcriptional compensation of the functional Cl- channel 1 gene dosage.

M F Chen1, R Niggeweg, P A Iaizzo, F Lehmann-Horn, H Jockusch.   

Abstract

1. In mature mammalian muscle, the muscular chloride channel ClC-1 contributes about 75% of the sarcolemmal resting conductance (Gm). In mice carrying two defective alleles of the corresponding Clc1 gene, chloride conductance (GCl) is reduced to less than 10% of that of wild-type, and this causes hyperexcitability, the salient feature of the disease myotonia. Potassium conductance (GK) values in myotonic mouse muscle fibres are lowered by about 60% compared with wild-type. 2. The defective Clcadr allele causes loss of the 4.5 kb ClC-1 mRNA. Mice heterozygous for the defective Clc1adr allele contain about 50% functional mRNA in their muscles compared with homozygous wild-type mice. 3. Despite a halved functional gene dosage, heterozygous muscles display an average GCl which is not significantly different from that of homozygous wild-type animals. The GK values in heterozygotes are also indistinguishable from homozygous wild-type animals. 4. These results indicate that a regulatory mechanism acting at the post-transcriptional level limits the density of ClC-1 channels. GK is probably indirectly regulated by muscle activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350619      PMCID: PMC1159937          DOI: 10.1111/j.1469-7793.1997.075bf.x

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  19 in total

1.  Biological features of the new A2G--adr mouse mutant with abnormal muscle function.

Authors:  W J Watkins; D C Watts
Journal:  Lab Anim       Date:  1984-01       Impact factor: 2.471

2.  Primary structure and functional expression of a developmentally regulated skeletal muscle chloride channel.

Authors:  K Steinmeyer; C Ortland; T J Jentsch
Journal:  Nature       Date:  1991-11-28       Impact factor: 49.962

3.  An analysis of the end-plate potential recorded with an intracellular electrode.

Authors:  P FATT; B KATZ
Journal:  J Physiol       Date:  1951-11-28       Impact factor: 5.182

4.  Activators of protein kinase C induce myotonia by lowering chloride conductance in muscle.

Authors:  H Brinkmeier; H Jockusch
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

5.  The genes for two neuromuscular diseases of the mouse, 'arrested development of righting response', adr, and 'myotonia', mto, are allelic.

Authors:  H Jockusch; K Bertram; S Schenk
Journal:  Genet Res       Date:  1988-12       Impact factor: 1.588

6.  Myotonia. An evaluation of the chloride hypothesis.

Authors:  R L Barchi
Journal:  Arch Neurol       Date:  1975-03

7.  Myotonia, a new inherited muscle disease in mice.

Authors:  A H Heller; E M Eicher; M Hallett; R L Sidman
Journal:  J Neurosci       Date:  1982-07       Impact factor: 6.167

8.  Inactivation of muscle chloride channel by transposon insertion in myotonic mice.

Authors:  K Steinmeyer; R Klocke; C Ortland; M Gronemeier; H Jockusch; S Gründer; T J Jentsch
Journal:  Nature       Date:  1991-11-28       Impact factor: 49.962

9.  Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH.

Authors:  F Lehmann-Horn; G Küther; K Ricker; P Grafe; K Ballanyi; R Rüdel
Journal:  Muscle Nerve       Date:  1987-05       Impact factor: 3.217

10.  The myotonic mouse mutant ADR: electrophysiology of the muscle fiber.

Authors:  G Mehrke; H Brinkmeier; H Jockusch
Journal:  Muscle Nerve       Date:  1988-05       Impact factor: 3.217

View more
  7 in total

1.  Intracellular β-nicotinamide adenine dinucleotide inhibits the skeletal muscle ClC-1 chloride channel.

Authors:  Brett Bennetts; Yawei Yu; Tsung-Yu Chen; Michael W Parker
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

2.  Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction.

Authors:  Christopher W Waters; Grigor Varuzhanyan; Robert J Talmadge; Andrew A Voss
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

3.  Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.

Authors:  S Pierno; G M Camerino; V Cippone; J-F Rolland; J-F Desaphy; A De Luca; A Liantonio; G Bianco; J D Kunic; A L George; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

Review 4.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

5.  A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  H L Martin; R B Mounsey; K Sathe; S Mustafa; M C Nelson; R M Evans; P Teismann
Journal:  Neuroscience       Date:  2013-03-07       Impact factor: 3.708

6.  Ultrasound-enhanced delivery of morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice.

Authors:  Michinori Koebis; Tamami Kiyatake; Hiroshi Yamaura; Kanako Nagano; Mana Higashihara; Masahiro Sonoo; Yukiko Hayashi; Yoichi Negishi; Yoko Endo-Takahashi; Dai Yanagihara; Ryoichi Matsuda; Masanori P Takahashi; Ichizo Nishino; Shoichi Ishiura
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  Impaired surface membrane insertion of homo- and heterodimeric human muscle chloride channels carrying amino-terminal myotonia-causing mutations.

Authors:  Katharina Ronstedt; Damien Sternberg; Silvia Detro-Dassen; Thomas Gramkow; Birgit Begemann; Toni Becher; Petra Kilian; Matthias Grieschat; Jan-Philipp Machtens; Günther Schmalzing; Martin Fischer; Christoph Fahlke
Journal:  Sci Rep       Date:  2015-10-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.